A detailed history of Mc Lean Asset Management Corp transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Mc Lean Asset Management Corp holds 263 shares of REGN stock, worth $184,586. This represents 0.08% of its overall portfolio holdings.

Number of Shares
263
Previous 263 -0.0%
Holding current value
$184,586
Previous $282 Million 5.44%
% of portfolio
0.08%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

SELL
$883.2 - $1071.19 $87,436 - $106,047
-99 Reduced 27.35%
263 $282 Million
Q1 2024

Apr 10, 2024

BUY
$902.69 - $993.35 $902 - $993
1 Added 0.28%
362 $342 Million
Q4 2023

Jan 08, 2024

SELL
$775.18 - $881.7 $2,325 - $2,645
-3 Reduced 0.82%
361 $330 Million
Q2 2023

Jul 10, 2023

SELL
$700.03 - $830.35 $700 - $830
-1 Reduced 0.27%
364 $262 Million
Q1 2023

Apr 11, 2023

SELL
$680.49 - $826.97 $2,721 - $3,307
-4 Reduced 1.08%
365 $300 Million
Q4 2022

Jan 19, 2023

BUY
$705.89 - $766.39 $2,823 - $3,065
4 Added 1.1%
369 $266 Million
Q3 2022

Oct 12, 2022

BUY
$573.97 - $724.32 $5,165 - $6,518
9 Added 2.53%
365 $264,000
Q2 2022

Jul 07, 2022

SELL
$548.35 - $738.84 $1,645 - $2,216
-3 Reduced 0.84%
356 $212,000
Q1 2022

Apr 08, 2022

BUY
$595.12 - $698.43 $5,356 - $6,285
9 Added 2.57%
359 $251,000
Q4 2021

Jan 14, 2022

SELL
$543.48 - $670.97 $30,434 - $37,574
-56 Reduced 13.79%
350 $221,000
Q2 2021

Jul 19, 2021

BUY
$472.8 - $558.54 $191,956 - $226,767
406 New
406 $237,000
Q1 2021

Apr 28, 2021

SELL
$446.73 - $548.2 $184,946 - $226,954
-414 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$478.3 - $607.98 $198,016 - $251,703
414 New
414 $200,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Mc Lean Asset Management Corp Portfolio

Follow Mc Lean Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Lean Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mc Lean Asset Management Corp with notifications on news.